Menu

Category: Uncategorized

Let’s Make TB History!

I visited South Africa earlier this year to learn more about the progress the country is making in the fight against HIV. I toured health clinics, met with doctors and researchers, and listened to the stories of people living with HIV. Again and again, our conversations turned to an often forgotten disease which is HIV’s […]

November 2, 2016 Uncategorized

New TB Clinical Trial Data-Sharing Platform Available for Researchers

TUCSON, Ariz., April 18, 2016 — The Critical Path Institute (C-Path), the Special Programme for Research and Training in Tropical Diseases (TDR), TB Alliance, andSt. George’s, University of London, are pleased to announce the launch of the TB-Platform for Aggregation of Clinical TB Studies (TB-PACTS). “TB-PACTS is a valuable tool in the fight against the […]

April 18, 2016 Drug Development Partner News Press Releases Regulatory Science Research Resources Uncategorized clinical trials drug development TB-PACTS

Losing the Fight Against Tuberculosis

by Patrick Adams Originally published by New York Times on January 5, 2015 On a recent morning at Persahabatan Hospital in East Jakarta, patients, some from remote villages accessible only by boat, gathered in a waiting room. Nearby, lab technicians used new diagnostic technology to test sputum samples for multidrug-resistant tuberculosis, in an effort to […]

January 8, 2015 Uncategorized
CPTR

3rd Annual CPTR Workshop

In October, the Critical Path to TB Drug Regimens (CPTR) initiative convened partners from the academic, foundation, government/regulatory, pharmaceutical and scientific communities in Washington, D.C. for its 3rd Annual Workshop. Participants reviewed individual and collective accomplishments in advancing new TB drug regimen development, as well as the current global and regulatory landscape and other cross-sector […]

December 17, 2012 Uncategorized
CPTR

Trial Signals Major Milestone in Hunt for New TB Drugs

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments, according to a study published in the Lancet.

August 9, 2012 Uncategorized
CPTR

CPTR Workshop Agenda Announced

CPTR will be hosting its second Workshop on November 9-10, 2011 at the Hilton Arlington in Arlington, VA. The Workshop will provide a forum for the workgroups to meet and receive updates on the latest state of the science. Click through this post to preview the latest agenda for the CPTR Workshop 2011

July 13, 2011 Events Uncategorized
CPTR

Critical Path Institute Announces Expansion of Regulatory Science Consortium for Tuberculosis

Critical Path Institute (C-Path) announced that the Regulatory Science Consortium, an arm of CPTR, has added 10 new member organizations, including some of the world’s leading pharmaceuitcal developers

April 29, 2011 Partner News Press Releases Uncategorized

NEJM Features FDA Commentary on Co-development

FDA’s Dr. Janet Woodcock writes about regimen development in the New England Journal of Medicine, noting that it is an important approach for drug development of therapies that can impact the human condition. She specifically calls out the need for information sharing through nonprofit groups and initiatives. Click here to read the article.

February 18, 2011 Uncategorized

Treatment Action Group Issues Global Tuberculosis Research & Development Update

A new report from the Treatment Action Group (TAG), a research and policy think tank, and the Global Stop TB Partnership, reveals that in 2009 – the last year for which full data are available – the world invested just $614 million in tuberculosis research and development.

November 11, 2010 Uncategorized

Lancet Article Highlights Hope in the Tuberculosis Drug Development Pipeline

According to a paper published today in The Lancet, there is unprecedented progress in the development of the global tuberculosis (TB) drug pipeline with 10 drug candidates currently in clinical development. The paper was written by a team of renowned international experts led by Zhenkun Ma, Ph.D., Chief Scientific Officer for the TB Alliance, a not-for-profit organization accelerating the discovery and development of new TB drugs.

May 19, 2010 Uncategorized